Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 22 May 2012
Vol. 5, Issue 225, p. pc11
[DOI: 10.1126/scisignal.2003176]


Science Signaling Podcast: 22 May 2012

Mari L. Shinohara1,2 and Annalisa M. VanHook3

1 Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
2 Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
3 Web Editor, Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005, USA.

Abstract: This Podcast features an interview with Mari Shinohara, senior author of a Research Article published in the 22 May 2012 issue of Science Signaling. Interferon-β (IFN-β) treatment can slow the progression of multiple sclerosis (MS) by reducing inflammation in the nervous system, but it is not effective in all patients. Mari Shinohara’s group studies the effects of IFN-β therapy in a mouse model of MS to understand how this protein can inhibit the inflammation that leads to neurological dysfuntion in human patients. They found that IFN-β therapy is only effective in treating symptoms in the mouse model when development of the disease depends upon the NLRP3 inflammasome, suggesting the possibility that this might also be the reason for the failure of IFN-β therapy in some human MS patients.

Citation: M. L. Shinohara, A. M. VanHook, Science Signaling Podcast: 22 May 2012. Sci. Signal. 5, pc11 (2012).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882